Enhanced therapeutic efficacy of 5'deoxy-5-fluorouridine in 5-fluorouracil resistant head and neck tumours in relation to 5-fluorouracil metabolising enzymes
Open Access
- 1 March 1989
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 59 (3) , 327-334
- https://doi.org/10.1038/bjc.1989.65
Abstract
Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug 5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR). 5-FU sensitivity at the maximum tolerated dose (MTD) showed the following pattern; HNX-DU less than HNX-KE = HNX-E = HNX-G less than Colon 26 much less than Colon 38. The sensitivity pattern to 5'd-FUR was: HNX-DU less than HNX-G less than HNX-E less than HNX-KE less than Colon 38 less than Colon 26. For HNX-KE, HNX-E and Colon 26 an increase in therapeutic efficacy was observed with 5'd-FUR as compared to 5-FU; Colon 38 was as sensitive to 5'd-FUR as to 5-FU. Plasma pharmacokinetics of 5'd-FUR and 5-FU were comparable in normal and nude mice. Metabolism of 5-FU and 5'd-FUR was studied in the tumours. Conversion of 5'd-FUR to 5-FU was highest in Colon 26 and 15-20 times lower in HNX-DU, HNX-KE and Colon 38. The Km for 5'd-FUR in all tumours was 1-2 mM. Further anabolism of 5-FU to fluorouridine (FUR) was 5-10 times higher than that of 5-FU to FUR in HNX tumours and 3 times in the colon tumours. 5-FU conversion to FUMP via FUR had the following pattern: Colon 26 much greater than HNX-DU greater than HNX-G greater than HNX-E greater than HNX-KE much greater than Colon 38; of 5-FU to FdUMP via FUdR: Colon 26 greater than HNX-DU = HNX-KE greater than HNX-E greater than HNX-G = Colon 38; and that of 5-FU to FUMP catalysed by orotate phosphoribosyl transferase (OPRT); Colon 26 greater than or equal to Colon 38 greater than HNX-KE greater than HNX-E = HNX-DU = HNX-G. Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential sensitivity.This publication has 32 references indexed in Scilit:
- A sensitive non-radioactive assay for pyrimidine nucleoside phosphorylase using reversed-phase high performance liquid chromatographyClinica Chimica Acta; International Journal of Clinical Chemistry, 1988
- A randomized comparison of doxifluridine and fluorouracil in colorectal carcinomaEuropean Journal of Cancer and Clinical Oncology, 1988
- Purine nucleosides as cell-specific modulators of 5-fluorouracil metabolism and cytotoxicityEuropean Journal of Cancer and Clinical Oncology, 1987
- Tissue homogenization using a micro-dismembrator for the measurement of enzyme activitiesClinica Chimica Acta; International Journal of Clinical Chemistry, 1986
- The degradation of 5′-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissuesClinica Chimica Acta; International Journal of Clinical Chemistry, 1985
- Separation of several 5-Fluorouracil metabolites in various melanoma cell lines. Evidence for the synthesis of 5-Fluorouracil-nucleotide sugarsEuropean Journal of Cancer and Clinical Oncology, 1984
- Phase II study of doxifluridine in advanced squamous cell carcinoma of the head and neckEuropean Journal of Cancer and Clinical Oncology, 1984
- Evidence that 5′-deoxy-5-fluorouridine may not be activated by the same mechanism as 5-fluorouracilBiochemical Pharmacology, 1982
- Tumor inhibitory effects of a new fluorouracil derivative: 5′-deoxy-5-fluorouridinePublished by Elsevier ,1980
- Determination of ribose 1-phosphate in ascites tumor cellsBiochemical Medicine, 1977